Advertisement
U.S. markets closed
  • S&P Futures

    5,141.75
    -4.25 (-0.08%)
     
  • Dow Futures

    39,082.00
    -60.00 (-0.15%)
     
  • Nasdaq Futures

    18,352.25
    +14.00 (+0.08%)
     
  • Russell 2000 Futures

    2,074.50
    -3.70 (-0.18%)
     
  • Crude Oil

    79.99
    +0.02 (+0.03%)
     
  • Gold

    2,089.50
    -6.20 (-0.30%)
     
  • Silver

    23.27
    -0.09 (-0.38%)
     
  • EUR/USD

    1.0848
    +0.0009 (+0.09%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • Vix

    13.11
    -0.29 (-2.16%)
     
  • GBP/USD

    1.2667
    +0.0012 (+0.09%)
     
  • USD/JPY

    150.1490
    +0.0850 (+0.06%)
     
  • Bitcoin USD

    63,541.23
    +1,456.43 (+2.35%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    40,138.77
    +227.95 (+0.57%)
     

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

Annexon Biosciences
Annexon Biosciences

BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will participate in a virtual panel titled, “Orphan CNS Panel,” during the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, to bring therapies to patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s proprietary complement-targeting platform utilizes well-researched classical complement-mediated autoimmune and neurodegenerative processes triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a broad portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway, which may provide more complete protection against complement-mediated disorders of the body, brain and eye. The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs. Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:

Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com


Advertisement